Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction
First Claim
1. A method of treating female sexual dysfunction which comprises administering to a female patient in need thereof a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides a method of treating female sexual dysfunction, the method comprising the step of administering to a patent, having or at risk of having one or more of the disorders or conditions associated with female sexual dysfunction, a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α-melanocyte stimulating hormone to melanocortin receptors. The present invention also provides a method of identifying a compound that is useful for the treatment or prevention of female sexual dysfunction, the method comprising the steps of: 1) determining if a compound affects the binding of agouti-related protein to melanocortin receptors; 2) determining if a compound affects the binding of α-melanocyte stimulating hormone to melanocortin receptors; and 3) selecting a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not affect the binding of α-melanocyte stimulating hormone to melanocortin receptors.
-
Citations
61 Claims
-
1. A method of treating female sexual dysfunction which comprises administering to a female patient in need thereof a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors.
- View Dependent Claims (2, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
-
3. A method of treating sexual arousal disorder in a female patient which comprises administering to a female patient in need thereof a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors.
-
4. A method of treating vaginismus in a female patient which comprises administering to a female patient in need thereof a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors.
-
5. A method of increasing the frequency or intensity of orgasms in a female patient which comprises administering to a female patient in need thereof a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors.
-
6. A method of enhancing libido more than normal in a female patient which comprises administering to a female patient in need thereof a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors.
-
27. A method of identifying a compound that is useful for the treatment of female sexual dysfunction which comprises the steps of:
-
1) determining if a compound affects the binding of agouti-related protein to melanocortin receptors;
2) determining if a compound affects the binding of α
-melanocyte stimulating hormone to melanocortin receptors; and
3) selecting a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
-melanocyte stimulating hormone to melanocortin receptors. - View Dependent Claims (28, 29, 30, 31, 32)
-
-
33. A pharmaceutical composition for treating female sexual dysfunction which comprises a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors.
-
34. A pharmaceutical composition for treating female sexual dysfunction which comprises 1) a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors; and
2) a compound that is a melanocortin receptor agonist.
- -melanocyte stimulating hormone to melanocortin receptors; and
-
35. A pharmaceutical composition which comprises 1) a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors, and
2) an estrogen agonist/antagonist or a pharmaceutically acceptable salt thereof. - View Dependent Claims (37, 38, 39, 40, 41, 42, 43, 44, 60, 61)
- -melanocyte stimulating hormone to melanocortin receptors, and
-
36. A pharmaceutical composition which comprises 1) a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors;
2) a compound that is a melanocortin receptor agonist; and
3) an estrogen agonist/antagonist or a pharmaceutically acceptable salt thereof.
- -melanocyte stimulating hormone to melanocortin receptors;
-
45. A pharmaceutical composition for treating female sexual dysfunction which comprises 1) a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors, and
2) a compound selected from the group consisting of a cyclic guanosine 3′
,5′
-monophosphate elevator. - View Dependent Claims (46, 47)
- -melanocyte stimulating hormone to melanocortin receptors, and
-
48. A pharmaceutical composition which comprises 1) a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors, and
2) an estrogen optionally with a progestin. - View Dependent Claims (49)
- -melanocyte stimulating hormone to melanocortin receptors, and
-
50. A pharmaceutical composition which comprises 1) a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors, and
2) a compound selected from the group consisting of Prostaglandins;
Apomorphine;
Oxytocin modulators;
α
-2 Adrenergic antagonists;
Androgens;
selective androgen receptor modulators (SARMs);
bupropion;
Vasoactive intestinal peptide (VIP);
Neutral endopeptidase inhibitors (NEP); and
Neuropeptide Y receptor antagonists (NPY).
- -melanocyte stimulating hormone to melanocortin receptors, and
-
51. A pharmaceutical composition for treating female sexual dysfunction which comprises 1) a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors;
2) a compound that is a melanocortin receptor agonist; and
3) a compound selected from the group consisting of a cyclic guanosine 3′
,5′
-monophosphate elevator. - View Dependent Claims (52, 53)
- -melanocyte stimulating hormone to melanocortin receptors;
-
54. A pharmaceutical composition which comprises 1) a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors;
2) a compound that is a melanocortin receptor agonist; and
3) an estrogen optionally with a progestin. - View Dependent Claims (55)
- -melanocyte stimulating hormone to melanocortin receptors;
-
56. A pharmaceutical composition which comprises 1) a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors;
2) a compound that is a melanocortin receptor agonist; and
3) a compound selected from the group consisting of Prostaglandins;
Apomorphine;
Oxytocin modulators;
α
-2 Adrenergic antagonists;
Androgens;
selective androgen receptor modulators (SARMs);
bupropion;
Vasoactive intestinal peptide (VIP);
Neutral endopeptidase inhibitors (NEP); and
Neuropeptide Y receptor antagonists (NPY).
- -melanocyte stimulating hormone to melanocortin receptors;
-
57. A pharmaceutical composition that comprises 1) a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors, which compound is useful to treat sexual arousal disorder, treat vaginismus, enhance libido more than normal or increase the frequency or intensity of orgasms;
2) a compound that is a melanocortin receptor agonist; and
3) a second compound useful to treat sexual arousal disorder, treat vaginismus, enhance libido more than normal or increase the frequency or intensity of orgasms.
- -melanocyte stimulating hormone to melanocortin receptors, which compound is useful to treat sexual arousal disorder, treat vaginismus, enhance libido more than normal or increase the frequency or intensity of orgasms;
-
58. A pharmaceutical composition that comprises 1) a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
- -melanocyte stimulating hormone to melanocortin receptors, which compound is useful to treat sexual arousal disorder, treat vaginismus, enhance libido more than normal or increase the frequency or intensity of orgasm; and
2) a second compound useful to treat sexual arousal disorder, treat vaginismus, enhance libido more than normal or increase the frequency or intensity of orgasms.
- -melanocyte stimulating hormone to melanocortin receptors, which compound is useful to treat sexual arousal disorder, treat vaginismus, enhance libido more than normal or increase the frequency or intensity of orgasm; and
-
59. A kit to treat sexual arousal disorder, treat vaginismus, enhance libido more than normal or increase the frequency or intensity of orgasms comprising:
-
a) a first pharmaceutical composition comprising a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of α
-melanocyte stimulating hormone to melanocortin receptors;
b) a second pharmaceutical composition comprising a second compound useful to treat sexual arousal disorder, treat vaginismus, enhance libido more than normal or increase the frequency or intensity of orgasms;
c) a container for the first and second compositions.
-
Specification